See more : Jindal Drilling & Industries Limited (JINDRILL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Axsome Therapeutics, Inc. (0HKF.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Axsome Therapeutics, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Changyou Alliance Group Limited (1039.HK) Income Statement Analysis – Financial Results
- Enad Global 7 AB (publ) (EG7.ST) Income Statement Analysis – Financial Results
- Valuence Holdings Inc. (9270.T) Income Statement Analysis – Financial Results
- Kingswood Holdings Limited (KWGHF) Income Statement Analysis – Financial Results
- Photon Control Inc. (PHO.TO) Income Statement Analysis – Financial Results
Axsome Therapeutics, Inc. (0HKF.L)
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.60M | 50.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.07M | 5.20M | 1.16M | 77.72K | 37.33K | 48.94K | 42.56K | 20.48K | 3.54K | 0.00 | 0.00 |
| Gross Profit | 244.54M | 44.84M | -1.16M | -77.72K | -37.33K | -48.94K | -42.56K | -20.48K | -3.54K | 0.00 | 0.00 |
| Gross Profit Ratio | 90.37% | 89.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 97.94M | 57.95M | 58.06M | 70.24M | 53.65M | 23.50M | 19.96M | 21.20M | 6.78M | 4.28M | 1.54M |
| General & Administrative | 222.82M | 123.95M | 66.65M | 28.90M | 13.60M | 9.35M | 7.21M | 6.34M | 2.42M | 1.39M | 304.18K |
| Selling & Marketing | 100.30M | 35.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 323.12M | 159.25M | 66.65M | 28.90M | 13.60M | 9.35M | 7.21M | 6.34M | 2.42M | 1.39M | 304.18K |
| Other Expenses | 55.29M | 4.14M | 0.00 | -53.58K | -139.45K | 217.42K | 207.11K | 474.28K | 0.00 | -184.14K | 0.00 |
| Operating Expenses | 476.36M | 221.34M | 124.71M | 99.09M | 67.11M | 32.63M | 26.96M | 27.07M | 9.20M | 5.49M | 1.84M |
| Cost & Expenses | 502.43M | 226.54M | 124.71M | 99.09M | 67.11M | 32.63M | 26.96M | 27.07M | 9.20M | 5.49M | 1.84M |
| Interest Income | 0.00 | 7.33M | 5.70M | 2.57M | 1.24M | 0.00 | 0.00 | 0.00 | 914.95K | 2.23M | 0.00 |
| Interest Expense | 6.45M | 7.33M | 5.70M | 2.57M | 1.24M | 1.13M | 1.34M | 132.42K | 914.95K | 2.23M | 327.19K |
| Depreciation & Amortization | 6.83M | 5.56M | 1.16M | 77.72K | 37.33K | 48.94K | 42.56K | 20.48K | 3.54K | 2.93M | 1.84M |
| EBITDA | -224.99M | -174.23M | -123.55M | -99.06M | -67.21M | -32.58M | -27.77M | -27.52M | -9.19M | -2.74M | 0.00 |
| EBITDA Ratio | -83.15% | -341.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -231.83M | -176.50M | -124.71M | -99.14M | -67.25M | -32.85M | -27.16M | -27.54M | -9.20M | -5.67M | -1.84M |
| Operating Income Ratio | -85.67% | -352.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.45M | -7.33M | -5.70M | -3.81M | -1.24M | 1.66M | -1.78M | 341.86K | -1.36M | -328.53K | -327.19K |
| Income Before Tax | -238.28M | -187.13M | -130.40M | -102.90M | -68.35M | -30.97M | -28.94M | -27.20M | -10.56M | -6.00M | -2.17M |
| Income Before Tax Ratio | -88.06% | -373.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 960.00K | 10.63M | 4.54M | 2.49M | 1.34M | 3.01M | 1.30M | 586.22K | 1.36M | -2.42M | -1.84M |
| Net Income | -239.24M | -197.77M | -134.94M | -105.39M | -69.69M | -30.97M | -28.94M | -27.20M | -10.56M | -6.00M | -2.17M |
| Net Income Ratio | -88.41% | -395.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.27 | -4.86 | -3.59 | -2.83 | -2.05 | -1.15 | -1.27 | -1.42 | -0.88 | -0.47 | -0.17 |
| EPS Diluted | -5.27 | -4.86 | -3.59 | -2.83 | -2.05 | -1.15 | -1.27 | -1.42 | -0.88 | -0.47 | -0.17 |
| Weighted Avg Shares Out | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M | 26.88M | 22.76M | 19.15M | 11.95M | 12.72M | 12.72M |
| Weighted Avg Shares Out (Dil) | 45.43M | 40.66M | 37.62M | 37.21M | 34.02M | 26.88M | 22.76M | 19.15M | 11.95M | 12.72M | 12.72M |
Source: https://incomestatements.info
Category: Stock Reports